바카라 게임 사이트

As cases of acute myocardial infarction (AMI) steadily increase in Korea, PCSK9 inhibitors are emerging as a promising solution for high-risk patients who fail to achieve 바카라 게임 사이트 (low-density lipoprotein cholesterol) targets with statins and ezetimibe.

According to updated data from the Health Insurance Review and Assessment Service (HIRA), 142,746 AMI patients (ICD code I21) were registered in 2023—marking a 74% rise from 81,824 바카라 게임 사이트 in 2014. Alarmingly, recurrence rates are rising even faster. The Korea Disease Control and Prevention Agency reported in December that the recurrence rate of myocardial infarction more than doubled over the past decade, reaching 6.6 바카라 게임 사이트 per 100,000 people in 2022—outpacing the 44% increase in initial 바카라 게임 사이트.

This trend is particularly concerning, as recurrent atherosclerotic cardiovascular disease (ASCVD) events, including heart attacks, are associated with significantly higher mortality. One in three patients who have experienced a heart attack or stroke is likely to suffer another event. Mortality rates for recurrent myocardial infarction are 2–3 times higher than first-time 바카라 게임 사이트, ranging from 68% to 85%.

In response, treatment guidelines in Korea have been updated to emphasize more aggressive 바카라 게임 사이트 lowering. The Korean Society of Cardiology’s Acute Coronary Syndrome (ACS) Research Group revised its guidelines in December 2024, recommending that ACS patients lower 바카라 게임 사이트 to below 55 mg/dL and achieve at least a 50% reduction from baseline. Similarly, the Korean Society of Lipid and Atherosclerosis now advises these same targets for coronary artery disease patients, aligning with global recommendations.

However, real-world data indicate that many high-risk patients still fail to meet these targets. A study published in February by Professors Young-Hak Kim and Aram Kim at Asan Medical Center analyzed 16,934 high-risk ASCVD patients. Only 33.7% achieved 바카라 게임 사이트 levels below 55 mg/dL within 4–12 weeks after hospital discharge.

Crucially, those who reached target 바카라 게임 사이트 levels within 3 months experienced an 11% lower risk of major adverse cardiovascular events (MACE) (adjusted hazard ratio [aHR]: 0.89, 95% CI: 0.82–0.96). Among ACS patients, the risk reduction was even greater at 27% (aHR: 0.73, 95% CI: 0.63–0.85).

“These findings highlight how early achievement of 바카라 게임 사이트 targets is key to reducing cardiovascular risk,” said Professor Chul-Min Ahn of Severance Cardiovascular Hospital. “The updated guidelines clearly recommend that very high-risk patients—such as those with prior myocardial infarction—reduce 바카라 게임 사이트 below 55 mg/dL and achieve over a 50% reduction from baseline.”

Professor Ahn stressed that PCSK9 inhibitors offer an effective second-line therapy for patients who do not meet 바카라 게임 사이트 goals with the standard combination of statins and ezetimibe.

Currently, three 바카라 게임 사이트 inhibitors are approved in Korea: Repatha (evolocumab, Amgen Korea), Praluent (alirocumab, Sanofi-Aventis), and Leqvio (inclisiran, Novartis Korea).

Repatha and Praluent are monoclonal antibodies, while Leqvio is a small interfering RNA (siRNA)-based therapy. All three have shown substantial 바카라 게임 사이트 reductions in phase 3 clinical trials.

In the FOURIER trial, Repatha reduced 바카라 게임 사이트 by about 60% to a median of 30 mg/dL at 48 weeks. It also significantly lowered the risks of myocardial infarction (–27%), stroke (–21%), and coronary revascularization (–22%) compared to placebo. Rapid 바카라 게임 사이트 reduction was seen from Day 1, and consistent lowering was observed in a subgroup of 181 Korean patients. Repatha also boasts the longest median follow-up data—8.6 years—supporting long-term safety and tolerability.

Praluent, evaluated in the ODYSSEY OUTCOMES trial, demonstrated a 15% reduction in MACE over 2.8 years in patients with ACS, including myocardial infarction and unstable angina. It achieved an average 바카라 게임 사이트 reduction of 54.7%, peaking at Week 4.

Leqvio, tested in the ORION-9, -10, and -11 trials, recorded 바카라 게임 사이트 reductions of 47.9%, 52.3%, and 49.9%, respectively, at Day 510. In ORION-18, which included 24% Korean participants, Leqvio achieved a 57.17% reduction by Day 330.

“For patients not achieving 바카라 게임 사이트 targets with maximum statin and ezetimibe therapy, PCSK9 inhibitors should be strongly considered,” Professor Ahn advised. “It is important that patients work with their healthcare providers to set and actively manage their 바카라 게임 사이트 goals.”

In Korea, Repatha and Praluent are currently approved and reimbursed for secondary prevention in ASCVD patients. Internationally, the American College of Cardiology (ACC) recommends monoclonal antibody-based 바카라 게임 사이트 inhibitors as initial treatment options, based on consistent safety and efficacy data from the FOURIER and ODYSSEY trials.